Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| Pompe Disease Overview | 8 | 1 |
| Therapeutics Development | 9 | 2 |
| Pipeline Products for Pompe Disease Overview | 9 | 1 |
| Pipeline Products for Pompe Disease Comparative Analysis | 10 | 1 |
| Pompe Disease Therapeutics under Development by Companies | 11 | 1 |
| Pompe Disease Therapeutics under Investigation by Universities/Institutes | 12 | 1 |
| Pompe Disease Pipeline Products Glance | 13 | 3 |
| Late Stage Products | 13 | 1 |
| Clinical Stage Products | 14 | 1 |
| Early Stage Products | 15 | 1 |
| Pompe Disease Products under Development by Companies | 16 | 1 |
| Pompe Disease Products under Investigation by Universities/Institutes | 17 | 1 |
| Pompe Disease Companies Involved in Therapeutics Development | 18 | 11 |
| Alexion Pharmaceuticals Inc | 18 | 1 |
| Amicus Therapeutics, Inc. | 19 | 1 |
| Audentes Therapeutics, Inc. | 20 | 1 |
| EpiVax, Inc. | 21 | 1 |
| Etubics Corporation | 22 | 1 |
| Genzyme Corporation | 23 | 1 |
| greenovation Biotech GmbH | 24 | 1 |
| Oxyrane Belgium NV | 25 | 1 |
| Pharming Group N.V. | 26 | 1 |
| RespireRx Pharmaceuticals Inc. | 27 | 1 |
| Sarepta Therapeutics, Inc. | 28 | 1 |
| Pompe Disease Therapeutics Assessment | 29 | 10 |
| Assessment by Monotherapy Products | 29 | 1 |
| Assessment by Combination Products | 30 | 1 |
| Assessment by Target | 31 | 2 |
| Assessment by Mechanism of Action | 33 | 2 |
| Assessment by Route of Administration | 35 | 2 |
| Assessment by Molecule Type | 37 | 2 |
| Drug Profiles | 39 | 23 |
| Antisense Oligonucleotide to Activate Lysosomal Alpha-Glucosidase for Pompe Disease Drug Profile | 39 | 1 |
| AT-982 Drug Profile | 40 | 2 |
| ATB-200 + miglustat Drug Profile | 42 | 2 |
| CX-1739 Drug Profile | 44 | 4 |
| CX-717 Drug Profile | 48 | 2 |
| Gene Therapy 1 to Activate Acid Alpha-Glucosidase for Pompe Disease Drug Profile | 50 | 1 |
| Gene Therapy 2 to Activate Acid Alpha-Glucosidase for Pompe Disease Drug Profile | 51 | 1 |
| Gene Therapy to Activate Acid Alpha-Glucosidase for Pompe Disease Drug Profile | 52 | 1 |
| GZ-402666 Drug Profile | 53 | 2 |
| MOSS-GAA Drug Profile | 55 | 1 |
| OXY-2810 Drug Profile | 56 | 1 |
| Recombinant Alpha Glucosidase Replacement for Pompe Disease Drug Profile | 57 | 1 |
| Recombinant Alpha Glucosidase Replacement for Pompe Disease Drug Profile | 58 | 1 |
| Recombinant Enzymes for Pompe, Fabry and Hunter Diseases Drug Profile | 59 | 1 |
| Synthetic Peptides for Pompe disease Drug Profile | 60 | 1 |
| VAL-1221 Drug Profile | 61 | 1 |
| Pompe Disease Dormant Projects | 62 | 1 |
| Pompe Disease Discontinued Products | 63 | 1 |
| Pompe Disease Product Development Milestones | 64 | 5 |
| Featured News &Press Releases | 64 | 1 |
| Mar 03, 2016: Sanofi Genzyme Presents Results from Phase 1/2 Study of Investigational Second-Generation Therapy for Pompe Disease | 64 | 1 |
| Sep 03, 2015: Valerion Therapeutics Announces Positive Results Of Non-Clinical Research Study at SSIEM Annual Symposium | 65 | 1 |
| May 11, 2015: Audentes Therapeutics To Present New Data On AT-002 at American Society of Gene and Cell Therapy Annual Meeting | 66 | 1 |
| May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX1739 in the Treatment of Respiratory Disorders | 66 | 1 |
| May 04, 2015: Cortex Pharmaceuticals Announces Publication of Research Results on the Use of Ampakines CX717 in the Treatment of Respiratory Disorders | 67 | 2 |
| Appendix | 69 | 2 |
| Methodology | 69 | 1 |
| Coverage | 69 | 1 |
| Secondary Research | 69 | 1 |
| Primary Research | 69 | 1 |
| Expert Panel Validation | 69 | 1 |
| Contact Us | 69 | 1 |
| Disclaimer | 70 | 1 |